Y-mAbs Therapeutics (YMAB -0.1%) announces encouraging data on omburtamab, a humanized B7-H3-targeting monoclonal antibody, in patients with desmoplastic small round cell tumors (DSRCT), a rare type of aggressive sarcoma that typically starts in the abdomen of pelvis. The results were presented at the Connective Tissue Oncology Society Annual Meeting in Tokyo.
A total of 33 patients underwent gross total resection (GTR) at Memorial Sloan Kettering in New York. 24 received whole abdominalpelvic intensity-modulated radiotherapy (WA-IMRT) plus omburtamab interperitoneal radio immunotherapy (IP-RIT) while nine patients received WA-IMRT alone.
Median overall survival (OS) in the omburtamab cohort was 59 months compared to 41 months in the other. Adding omburtamab IP-RIT to GTR improved the five-year Kaplan Meier estimated OS from a historical rate of ~20% to ~40%.
Development is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.